V-Wave

Miniature Shunt for Treating Congestive Heart Failure

Health Tech & Life Sciences
Acquired by Johnson & Johnson on Aug, 2024
Acquired Caesarea Founded 2009
Total raised
$132.5M
Last: Series C 2020-09
Stage
Acquired
Founded
2009
Headcount
43
HQ
Caesarea
Sector
Health Tech & Life Sciences

About

V-Wave is focused on developing percutaneous implantable devices for treating patients with chronic heart failure. The companys vision is to help patients with disabling symptoms or who need hospitalization despite optimized medical treatment. V-Wave has developed the V-Wave Shunt, a miniature, biocompatible implant that regulates left atrial pressure (LAP), a primary cause of worsening symptoms that lead to over three million hospitalizations a year. The proprietary, unidirectional, interatrial shunt is designed to prevent episodes of elevated LAP, thereby improving symptoms, reducing hospitalizations, and increasing exercise tolerance and quality of life.

Funding history · 4 rounds · $132.5M total

2020-09
Series C $98.0M
2016-01
Series B $28.0M
2013-07
Series A $2.0M
2012-01
Seed $4.5M

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcareProvidersPatients
Business model
B2B

Highlights

1 Patents

Tags

medical-devicesvalvespatientscardiologyhospitalssurgeryheart-failurechronic-patientsminimally-invasive